Fragile X-Syndrome Market size was valued at USD 135.2 Mn. in 2024, growing at a CAGR of 5.43% to reach USD 206.39 Mn. Driven by clinical breakthroughs and AI innovation.Fragile X-Syndrome Market Overview
Fragile X-Syndrome utilizes semi-permeable membrane modules for precise separation, purification, and concentration in biopharmaceuticals, water treatment, and food processing. The Fragile X-Syndrome market encompasses polymeric (PVDF, PES) and ceramic membranes by their efficiency in microfiltration and ultrafiltration applications. Key growth is promoted by rising biopharmaceutical production, mainly for monoclonal antibodies and vaccines, alongside stringent water treatment regulations. Demand surges as industries adopt continuous manufacturing, while supply expands with advancements in fouling-resistant membranes and modular systems. North America leads by its advanced bioprocessing adoption and major industry players, while Asia Pacific emerges as fastest fastest-growing market, leveraging cost-efficient manufacturing and increasing biopharma investments. The pharmaceutical sector remains the largest end-user, contributing over 30% of revenue, with tariffs on raw materials like polymers occasionally impacting production costs. Sustainability trends and regulatory shifts toward single-use technologies further shape market dynamics, ensuring long-term growth. The report covers the Fragile X-Syndrome Market dynamics, structure by analyzing the market segments and projecting the Fragile X-Syndrome Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Fragile X-Syndrome Market.To know about the Research Methodology :- Request Free Sample Report
Fragile X-Syndrome Market Segment Analysis
The report groups the Global Fragile X-Syndrome Market into different segments by Product, End User, and Region to forecast the revenues and analyze the market share of each segment over the forecast period. Based on Product, the Global Fragile X-Syndromes Market is segmented into ACT-01, AMO-01, ANAVEX-273, and AUT-00206. ACT-01 dominated the Global Fragile X-Syndromes Market in 2024. This dominance is attributed to its advanced stage of clinical development, strong efficacy data, and broader therapeutic potential compared to other candidates. Additionally, ACT-01 has gained significant investor and pharmaceutical industry support, leading to faster commercialization prospects. Its ability to address core symptoms of Fragile X syndrome, such as cognitive and behavioral impairments, further strengthens its market position over competitors like AMO-01, ANAVEX-273, and AUT-00206, which are still in earlier developmental phases. Based on End User, the Global Fragile X-Syndromes Market is segmented into clinics, hospitals, and research centers. The Research Centers Segment dominated in 2024. To improve the diagnosis and treatment of Fragile X syndrome and its related conditions, the Centers for Collaborative Research are conducting a research program for syndrome detection and diagnosis. These centers are geared toward stimulating multidisciplinary, multi-institutional research on genetic disorders. The National Institute of Chronic Hereditary Disorders is one and many other intramural and extramural organizations that support and conduct a broad range of research on Fragile X syndrome. Many researchers are studying fragile X-associated disorders, having the main focus being to find out the fragile X-associated primary ovarian insufficiency and fragile X-associated tremor syndrome. The NICHD-supported research groups are seeking ways to better diagnose and screen newborns for Fragile X mutations and permutations. There are many new arrivals of technological designs that are applied to detect fragile X alleles and other gene mutations. There are many programs conducted by many government and non-government organizations on genetic disorders to raise awareness among the global population. FRAXA Research Foundation is a research organization that conducts a detailed study on the Fragile X-Syndrome. The research group has invested US $ 30, 692, 922 on the fragile X syndrome. These kinds of activities by the research centers drive the global fragile X-syndrome market.Fragile X-Syndrome Market Regional Insights
North America is expected to command the largest market share by 2032 All guideline committees and American College of Medical Genetics (ACMG) professionals assist healthcare professionals in making decisions regarding genetic diagnosis and testing. Laboratory infrastructure and early intervention services help people learn important skills. Therapy and medicines are also available to control the gene mutations and their effects on other disorders. Local public school systems provide services and support for children aged 3 years and older, and those who are also suffering from genetic disorders. The help centers help fragile X syndrome disorder families helps learn how and where to have their children evaluated and how to find services.Fragile X-Syndrome Market Competitive Landscape
The Fragile X-Syndrome (FXS) market in 2024 is shaped by a competitive landscape with leading players leveraging innovation, AI, and clinical development. Zynerba Pharmaceuticals leads with Zygel, a transdermal cannabinoid gel in Phase 3 trials, targeting behavioral symptoms in FXS. Tetra Therapeutics is advancing BPN14770, showing a 30–40% improvement in cognitive and behavioral scores in Phase II trials, with backing from the NIH and private investors. Neuren Pharmaceuticals, after success with trofinetide for Rett Syndrome (FDA-approved in 2023), is targeting Fragile X with similar neurodevelopmental pathways through its U.S. partnership with Acadia Pharmaceutical. Marinus Pharmaceuticals is developing ganaxolone, and gained FDA approval for CDKL5 deficiency disorder in 2022, and is now in FXS trials. Healx, using AI to repurpose drugs, has identified over 20 novel candidates for rare diseases, including Fragile X, with multiple Phase I/II collaborations. These companies are top players due to their strong clinical pipelines, orphan drug designations, strategic licensing agreements, and focus on the underserved patient population. Their innovations aim to offer targeted, efficient, and scalable therapies for Fragile X-Syndrome, positioning them ahead in the race for market approval and commercial success.Fragile X-Syndrome Market Key Trends
Trend Description Advancements in Gene Therapy Researchers are exploring gene-editing tools (e.g., CRISPR-Cas9) and gene replacement therapies to correct the FMR1 gene mutation, which causes Fragile X syndrome. Early-stage trials show promise in restoring FMRP protein function, potentially offering a long-term cure rather than just symptom management. Rise in Precision Medicine Pharmaceutical companies are developing targeted therapies based on a patient’s genetic profile, allowing for personalized treatment plans. Biomarker research is helping identify subtypes of Fragile X, enabling more effective and tailored drug development. Expansion of Clinical Trials The pipeline for Fragile X treatments is growing, with several drugs (e.g., ACT-01, ANAVEX-273, AUT-00206) advancing to Phase 2/3 trials. Increased funding and regulatory incentives (e.g., orphan drug designations) are accelerating research. Fragile X-Syndrome Market Key Recent Development
Zynerba Pharmaceuticals (USA) Dec 21, 2022: Delayed topline results from the pivotal Phase 3 RECONNECT trial of Zygel™ (CBD transdermal gel) to H1 2024 due to disruptions from RSV, flu, and COVID‑19 (“Tripledemic”). May 11, 2022: Presented long-term safety and efficacy data of Zygel in children/adolescents with Fragile X-Syndrome at a conference, showing sustained improvements. Tetra Therapeutics (USA) Jul 18, 2024: Shionogi reported protocol amendments to improve access for participants in the zatolmilast (BPN14770) Fragile X-Syndrome development program; zatolmilast has Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Mar 21, 2025: FRAXA confirmed that adult (EXPERIENCE-301) enrollment is full, and adolescent (EXPERIENCE-204) enrollment is in its final phase. Neuren Pharmaceuticals (USA) Jul 13, 2023: Acadia expanded licensing terms for trofinetide and NNZ‑2591 in Rett and Fragile X syndromes.Fragile X-Syndrome Market Report Scope: Inquire before buying
Global Fragile X-Syndrome Market Report Coverage Details Base Year: 2024 Forecast Period: 2025-2032 Historical Data: 2019 to 2024 Market Size in 2024: USD 135.2 Mn Forecast Period 2025 to 2032 CAGR: 5.43% Market Size in 2032: USD 206.39 Mn Segments Covered: by Product Type ACT-01 AMO-01 ANAVEX-273 AUT-00206 by End User Clinics Hospitals Research Centers Fragile X-Syndrome Market, by region
North America (United States, Canada and Mexico) Europe (United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, Rest of Europe) Asia Pacific (China, Japan, South Korea, India, Australia, Malaysia, Thailand, Vietnam, Indonesia, Philippines, Rest of APAC) Middle East and Africa (South Africa, GCC, Nigeria, Egypt, Turkey, Rest of MEA) South America (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America)Fragile X-Syndrome Market Key Players
North America 1. Zynerba Pharmaceuticals (USA) 2. Tetra Therapeutics (USA) 3. Neuren Pharmaceuticals (USA) 4. Marinus Pharmaceuticals (USA) 5. Agilis Biotherapeutics (USA) 6. Fulcrum Therapeutics (USA) 7. Ovid Therapeutics (USA) 8. Confluence Pharmaceuticals (USA) 9. BioMarin Pharmaceutical (USA) Europe 10. Healx (UK) 11. Roche (Switzerland) 12. Novartis (Switzerland) 13. Servier Laboratories (France) 14. UCB Pharma (Belgium) 15. H. Lundbeck A/S (Denmark) Asia Pacific 16. Otsuka Pharmaceutical (Japan) 17. Sumitomo Pharma (Japan) 18. Eisai Co., Ltd. (Japan) 19. SK Biopharmaceuticals (South Korea) 20. Sun Pharmaceutical Industries (India) 21. Dr. Reddy’s Laboratories (India) Middle East & Africa 22. Aspen Pharmacare (South Africa) 23. Tabuk Pharmaceuticals (Saudi Arabia) South America 24. EMS Pharma (Brazil) 25. Eurofarma (Brazil) 26. Ache Laboratórios Farmacêuticos (Brazil) 27. Laboratorios Bagó (Argentina)Frequently Asked Questions:
1] What are the leading market players active in the Fragile X-Syndrome Market? Ans. The leading market players active in the Fragile X-Syndrome Market are Zynerba Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Marinus Pharmaceuticals, Roche, Novartis, Healx, and Fulcrum Therapeutics. 2] What is the market in the Fragile X-Syndrome Market in 2024? Ans. The market size in the Fragile X-Syndrome Market in 2024 is USD 135.2 Million. 3] What is the market in the Fragile X-Syndrome Market in 2032? Ans. The market size in the Fragile X-Syndrome Market in 2032 is USD 206.39 Million. 4] What is the projection period for the future that would help in taking further strategic steps? Ans. The Projections period for the future strategy for Fragile X-Syndrome Market is 2024-2032. 5] What Segments and regions will drive the Fragile X-Syndrome market growth? Ans. The Segments and regions that drive the Fragile X-Syndrome market growth are Product Type, End-User, and the region is North America.
1. Fragile X-Syndrome Market Introduction 1.1. Study Assumptions and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Global Fragile X-Syndrome Market: Competitive Landscape 2.1. Ecosystem Analysis 2.2. MMR Competition Matrix 2.3. Competitive Landscape 2.4. Key Players Benchmarking 2.4.1. Company Name 2.4.2. Service Segment 2.4.3. End-User Segment 2.4.4. Revenue (2024) 2.4.5. Geographical Presence 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 2.7. KANO Model Analysis 3. Fragile X-Syndrome Market: Dynamics 3.1. Region-wise Trends of Fragile X-Syndrome Market 3.1.1. North America Fragile X-Syndrome Market Trends 3.1.2. Europe Fragile X-Syndrome Market Trends 3.1.3. Asia Pacific Fragile X-Syndrome Market Trends 3.1.4. Middle East and Africa Fragile X-Syndrome Market Trends 3.1.5. South America Fragile X-Syndrome Market Trends 3.2. Fragile X-Syndrome Market Dynamics 3.2.1. Fragile X-Syndrome Market Drivers 3.2.1.1. Genetic Inheritance Risk 3.2.1.2. Rising Male Prevalence 3.2.2. Fragile X-Syndrome Market Restraints 3.2.3. Fragile X-Syndrome Market Opportunities 3.2.3.1. Counselling Development 3.2.3.2. Ethnic Group Screening 3.2.4. Fragile X-Syndrome Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Analysis 3.4.1. State-Level Support 3.4.2. Cost-Effective Testing 3.4.3. Advanced Diagnostics 3.5. Regulatory Landscape by Region 3.6. Key Opinion Leader Analysis for the Global Industry 3.7. Analysis of Government Schemes and Initiatives for Industry 4. Fragile X-Syndrome Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 4.1. Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 4.1.1. ACT-01 4.1.2. AMO-01 4.1.3. ANAVEX-273 4.1.4. AUT-00206 4.2. Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 4.2.1. Clinics 4.2.2. Hospitals 4.2.3. Research Centers 4.3. Fragile X-Syndrome Market Size and Forecast, By Region (2024-2032) 4.3.1. North America 4.3.2. Europe 4.3.3. Asia Pacific 4.3.4. Middle East and Africa 4.3.5. South America 5. North America Fragile X-Syndrome Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 5.1. North America Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 5.1.1. ACT-01 5.1.2. AMO-01 5.1.3. ANAVEX-273 5.1.4. AUT-00206 5.2. North America Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 5.2.1. Clinics 5.2.2. Hospitals 5.2.3. Research Centers 5.3. North America Fragile X-Syndrome Market Size and Forecast, by Country (2024-2032) 5.3.1. United States 5.3.1.1. United States Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 5.3.1.1.1. ACT-01 5.3.1.1.2. AMO-01 5.3.1.1.3. ANAVEX-273 5.3.1.1.4. AUT-00206 5.3.1.2. United States Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 5.3.1.2.1. Clinics 5.3.1.2.2. Hospitals 5.3.1.2.3. Research Centers 5.3.2. Canada 5.3.2.1. Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 5.3.2.1.1. ACT-01 5.3.2.1.2. AMO-01 5.3.2.1.3. ANAVEX-273 5.3.2.1.4. AUT-00206 5.3.2.2. Canada Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 5.3.2.2.1. Clinics 5.3.2.2.2. Hospitals 5.3.2.2.3. Research Centers 5.3.3. Mexico 5.3.3.1. Mexico Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 5.3.3.1.1. ACT-01 5.3.3.1.2. AMO-01 5.3.3.1.3. ANAVEX-273 5.3.3.1.4. AUT-00206 5.3.3.2. Mexico Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 5.3.3.2.1. Clinics 5.3.3.2.2. Hospitals 5.3.3.2.3. Research Centers 6. Europe Fragile X-Syndrome Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 6.1. Europe Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.2. Europe Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 6.3. Europe Fragile X-Syndrome Market Size and Forecast, by Country (2024-2032) 6.3.1. United Kingdom 6.3.1.1. United Kingdom Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.3.1.2. United Kingdom Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 6.3.2. France 6.3.2.1. France Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.3.2.2. France Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 6.3.3. Germany 6.3.3.1. Germany Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.3.3.2. Germany Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 6.3.4. Italy 6.3.4.1. Italy Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.3.4.2. Italy Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 6.3.5. Spain 6.3.5.1. Spain Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.3.5.2. Spain Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 6.3.6. Sweden 6.3.6.1. Sweden Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.3.6.2. Sweden Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 6.3.7. Russia 6.3.7.1. Russia Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.3.7.2. Russia Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 6.3.8. Rest of Europe 6.3.8.1. Rest of Europe Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 6.3.8.2. Rest of Europe Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7. Asia Pacific Fragile X-Syndrome Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032) 7.1. Asia Pacific Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.2. Asia Pacific Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3. Asia Pacific Fragile X-Syndrome Market Size and Forecast, by Country (2024-2032) 7.3.1. China 7.3.1.1. China Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.1.2. China Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.2. S Korea 7.3.2.1. S Korea Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.2.2. S Korea Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.3. Japan 7.3.3.1. Japan Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.3.2. Japan Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.4. India 7.3.4.1. India Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.4.2. India Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.5. Australia 7.3.5.1. Australia Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.5.2. Australia Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.6. Indonesia 7.3.6.1. Indonesia Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.6.2. Indonesia Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.7. Malaysia 7.3.7.1. Malaysia Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.7.2. Malaysia Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.8. Philippines 7.3.8.1. Philippines Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.8.2. Philippines Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.9. Thailand 7.3.9.1. Thailand Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.9.2. Thailand Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.10. Vietnam 7.3.10.1. Vietnam Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.10.2. Vietnam Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 7.3.11. Rest of Asia Pacific 7.3.11.1. Rest of Asia Pacific Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 7.3.11.2. Rest of Asia Pacific Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 8. Middle East and Africa Fragile X-Syndrome Market Size and Forecast (by Value in USD Million) (2024-2032 8.1. Middle East and Africa Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 8.2. Middle East and Africa Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 8.3. Middle East and Africa Fragile X-Syndrome Market Size and Forecast, by Country (2024-2032) 8.3.1. South Africa 8.3.1.1. South Africa Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 8.3.1.2. South Africa Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 8.3.2. GCC 8.3.2.1. GCC Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 8.3.2.2. GCC Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 8.3.3. Egypt 8.3.3.1. Egypt Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 8.3.3.2. Egypt Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 8.3.4. Nigeria 8.3.4.1. Nigeria Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 8.3.4.2. Nigeria Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 8.3.5. Rest of ME&A 8.3.5.1. Rest of ME&A Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 8.3.5.2. Rest of ME&A Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 9. South America Fragile X-Syndrome Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032 9.1. South America Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 9.2. South America Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 9.3. South America Fragile X-Syndrome Market Size and Forecast, by Country (2024-2032) 9.3.1. Brazil 9.3.1.1. Brazil Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 9.3.1.2. Brazil Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 9.3.2. Argentina 9.3.2.1. Argentina Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 9.3.2.2. Argentina Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 9.3.3. Colombia 9.3.3.1. Colombia Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 9.3.3.2. Colombia Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 9.3.4. Chile 9.3.4.1. Chile Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 9.3.4.2. Chile Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 9.3.5. Rest Of South America 9.3.5.1. Rest Of South America Fragile X-Syndrome Market Size and Forecast, By Product Type (2024-2032) 9.3.5.2. Rest Of South America Fragile X-Syndrome Market Size and Forecast, By End User (2024-2032) 10. Company Profile: Key Players 10.1. Zynerba Pharmaceuticals (USA) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Recent Developments 10.2. Tetra Therapeutics (USA) 10.3. Neuren Pharmaceuticals (USA) 10.4. Marinus Pharmaceuticals (USA) 10.5. Agilis Biotherapeutics (USA) 10.6. Fulcrum Therapeutics (USA) 10.7. Ovid Therapeutics (USA) 10.8. Confluence Pharmaceuticals (USA) 10.9. BioMarin Pharmaceutical (USA) 10.10. Healx (UK) 10.11. Roche (Switzerland) 10.12. Novartis (Switzerland) 10.13. Servier Laboratories (France) 10.14. UCB Pharma (Belgium) 10.15. H. Lundbeck A/S (Denmark) 10.16. Otsuka Pharmaceutical (Japan) 10.17. Sumitomo Pharma (Japan) 10.18. Eisai Co., Ltd. (Japan) 10.19. SK Biopharmaceuticals (South Korea) 10.20. Sun Pharmaceutical Industries (India) 10.21. Dr. Reddy’s Laboratories (India) 10.22. Aspen Pharmacare (South Africa) 10.23. Tabuk Pharmaceuticals (Saudi Arabia) 10.24. EMS Pharma (Brazil) 10.25. Eurofarma (Brazil) 10.26. Ache Laboratórios Farmacêuticos (Brazil) 10.27. Laboratorios Bagó (Argentina) 11. Key Findings 12. Industry Recommendations
